Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
// Andreia Peixoto 1, 2, 3, 4, * , Elisabete Fernandes 1, 3, 4, 5, * , Cristiana Gaiteiro 1, * , Luís Lima 1, 3, 6 , Rita Azevedo 1, 4 , Janine Soares 1 , Sofia Cotton 1 , Beatriz Parreira 1 , Manuel Neves 1, 4 , Teresina Amaro 7 , Ana Tavares 1, 7 , Filipe Teixeira 8 , Carlos Palmeira 1, 9 , Maria Rangel 10 , André M.N. Silva 11 , Celso A. Reis 3, 4, 6, 12 , Lúcio Lara Santos 1, 9, 13 , Maria José Oliveira 2, 3 , José Alexandre Ferreira 1, 3, 4, 6, 14 1 Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal 2 New Therapies Group, INEB-Institute for Biomedical Engineering, Porto, Portugal 3 Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal 4 Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal 5 Biomaterials for Multistage Drug and Cell Delivery, INEB-Institute for Biomedical Engineering, Porto, Portugal 6 Glycobiology in Cancer, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal 7 Department of Pathology, Hospital Pedro Hispano, Matosinhos, Portugal 8 LAQV-REQUIMTE, Faculty of Sciences of the University of Porto, Porto, Portugal 9 Health School of University Fernando Pessoa, Porto, Portugal 10 UCIBIO-REQUIMTE, Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal 11 UCIBIO-REQUIMTE/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto, Portugal 12 Department of Pathology and Oncology, Faculty of Medicine, Porto University, Porto, Portugal 13 Department of Surgical Oncology, Portuguese Institute of Oncology, Porto, Portugal 14 Porto Comprehensive Cancer Center (P.ccc), Porto, Portugal * These authors contributed equally to this work Correspondence to: José Alexandre Ferreira, email: josef@ipatimup.pt Keywords: glycosylation, bladder cancer, hypoxia, invasion, sialyl-Tn Received: September 24, 2015 Accepted: July 26, 2016 Published: August 12, 2016 ABSTRACT Invasive bladder tumours express the cell-surface Sialyl-Tn (STn) antigen, which stems from a premature stop in protein O-glycosylation. The STn antigen favours invasion, immune escape, and possibly chemotherapy resistance, making it attractive for target therapeutics. However, the events leading to such deregulation in protein glycosylation are mostly unknown. Since hypoxia is a salient feature of advanced stage tumours, we searched into how it influences bladder cancer cells glycophenotype, with emphasis on STn expression. Therefore, three bladder cancer cell lines with distinct genetic and molecular backgrounds (T24, 5637 and HT1376) were submitted to hypoxia. To disclose HIF-1α-mediated events, experiments were also conducted in the presence of Deferoxamine Mesilate (Dfx), an inhibitor of HIF-1α proteasomal degradation. In both conditions all cell lines overexpressed HIF-1α and its transcriptionally-regulated protein CA-IX. This was accompanied by increased lactate biosynthesis, denoting a shift toward anaerobic metabolism. Concomitantly, T24 and 5637 cells acquired a more motile phenotype, consistent with their more mesenchymal characteristics. Moreover, hypoxia promoted STn antigen overexpression in all cell lines and enhanced the migration and invasion of those presenting more mesenchymal characteristics, in an HIF-1α-dependent manner. These effects were reversed by reoxygenation, demonstrating that oxygen affects O -glycan extension. Glycoproteomics studies highlighted that STn was mainly present in integrins and cadherins, suggesting a possible role for this glycan in adhesion, cell motility and invasion. The association between HIF-1α and STn overexpressions and tumour invasion was further confirmed in bladder cancer patient samples. In conclusion, STn overexpression may, in part, result from a HIF-1α mediated cell-survival strategy to adapt to the hypoxic challenge, favouring cell invasion. In addition, targeting STn-expressing glycoproteins may offer potential to treat tumour hypoxic niches harbouring more malignant cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
STRING v10: protein–protein interaction networks, integrated over the tree of life
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1003 · Cited by 10,436 · cited 2×
“Protein molecular and biological functions were interpreted using PHANTER (Protein ANalysis THrough Evolutionary Relationships) [80] and Protein-Protein interactions explored using STRING v10 [45].”
Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W.-H., Pagès, F., Trajanoski, Z., & Galon, J. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp101 · Cited by 6,280 · cited 1×
“5 [76] and CluePedia plugins version 1.”
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502 · cited 1×
“A significant decrease in cell proliferation is also observed under hypoxia and Dfx (Supplementary Figure S2), which is consistent with previous reports regarded with hypoxia and HIF-1α mediated events [29, 30].”
Actin stress fibers – assembly, dynamics and biological roles
Tojkander, S., Gateva, G., & Lappalainen, P. (2012) · Journal of Cell Science · doi:10.1242/jcs.098087 · Cited by 900 · cited 1×
“These contractile actomyosin bundles anchored to focal adhesions connect the extracellular matrix (ECM) to the actin cytoskeleton and convert mechanical signals into biochemical cues, having an important role in focal adhesion maturation and dynamics [32].”
Loss of PTEN facilitates HIF-1-mediated gene expression
Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., et al. (2000) · Genes & Development · doi:10.1101/gad.14.4.391 · Cited by 840
The updated biology of hypoxia-inducible factor
Greer, S. N., Metcalf, J. L., Wang, Y., & Ohh, M. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.125 · Cited by 545 · cited 3×
“The primary factor mediating cellular responses to hypoxia is the hypoxiainducible factor-1α (HIF-1α), which transcriptional activity is oxygen-dependent [3, 4].”
Cosse, J.-P., & Michiels, C. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008785914798 · Cited by 348 · cited 1×
“A significant decrease in cell proliferation is also observed under hypoxia and Dfx (Supplementary Figure S2), which is consistent with previous reports regarded with hypoxia and HIF-1α mediated events [29, 30].”
Hassinen, A., Pujol, F. M., Kokkonen, N., Pieters, C., Kihlström, M., Korhonen, K., & Kellokumpu, S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277681 · Cited by 131 · cited 1×
“However, epigenetic changes such as hypermethylation of Cosmc [54], alterations in pH [55], and relocation of GalNAc-transferases from the Golgi to the endoplasmic reticulum [56] may also account for a premature stop in O-glycosylation.”
Akita, K., Yoshida, S., Ikehara, Y., Shirakawa, S., Toda, M., Inoue, M., Kitawaki, J., Nakanishi, H., Narimatsu, H., & Nakada, H. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e3182473292 · Cited by 54
Cited by
Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks
Peixoto, A., Relvas-Santos, M., Azevedo, R., Santos, L. L., & Ferreira, J. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00380 · Cited by 334
Self-citationClinical therapies and nano drug delivery systems for urinary bladder cancer
Jain, P., Kathuria, H., & Momin, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107871 · Cited by 89
Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?
Azevedo, R., Peixoto, A., Gaiteiro, C., Fernandes, E., Neves, M., Lima, L., Santos, L. L., & Ferreira, J. A. (2017) · Oncotarget · doi:10.18632/oncotarget.19433 · Cited by 39
“Studies in vitro have further demonstrated that this antigen plays an important role in bladder cancer cell migration and invasion through mechanisms so far unexplored [64, 69].”
BackgroundResultInfluentialSelf-citationHassinen, A., Khoder-Agha, F., Khosrowabadi, E., Mennerich, D., Harrus, D., Noel, M., Dimova, E. Y., Glumoff, T., Harduin-Lepers, A., Kietzmann, T., et al. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101182 · Cited by 33
Metadata
- Authors
- Peixoto, A., Fernandes, E., Gaiteiro, C., Lima, L., Azevedo, R., Soares, J., Cotton, S., Parreira, B., Neves, M., Amaro, T., Tavares, A., Teixeira, F., Palmeira, C., Rangel, M., Silva, A. M. N., Reis, C. A., Santos, L. L., Oliveira, M. J., & Ferreira, J. A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-08-12
- Volume
- 7
- Issue
- 39
- Pages
- 63138-63157
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2516991121
- Cited by
- 73
- References
- 11
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.